Evaluation of the effect of aspirin and clopidogrel on antiplatelet effects in coronary atherosclerotic heart disease patients with chronic kidney disease by thrombelastograph
CHEN Yi-lun
LI Jing-jing
GENG Xiao-wen
GAO Jie
REN Yi-hong
LIU Guo-shu
Abstract：Objective:To determine inhibitory effects of aspirin and clopidogrel on platelets in coronary atherosclerotic heart disease (CHD) patients with chronic kidney disease (CKD), and provide reference for clinical drug use.Methods:By retrospective method, the CHD patients whose diagnoses were conifrmed by coronary angiography were classiifed into two groups according to eGFR (Group A: CHD without CKD group; Group B: CHD with CKD group). All of the patients took aspirin 0.1 g and clopidogrel 75 mg every day at least for 7 days, or aspirin 0.3 g and clopidogrel 300 mg before the PCI operation, and then the inhibitory rates of arachidonic acid (AA%) and ADP receptor pathway (ADP%) on platelets were detected by the thrombelastograph (TEG). The sensitivities of aspirin and clopidogrel were estimated based on results of AA% or ADP%. SPSS20.0 software was used for statistical analysis.Results: The difference between aspirin and clopidogrel on antiplatelet sensitivity in CHD with normal renal function group (A group,n = 178) was not signiifcant (P = 0.345). But in CHD with renal insufifciency group (B group,n = 144), the antiplatelet sensitivity of clopidogrel was inferior to that of aspirin with signiifcant different (P = 0.012).Conclusion:There was no signiifcant difference between aspirin and clopidogrel on antiplatelet effect in CHD with normal kidney function. While, clopidogrel induced less platelet inhibition than aspirin in CHD patients with CKD.
Keywords：Coronary artery heart diseaseChronic kidney diseaseThrombelastographAspirinClopidogrel
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 141-143,181 )